Pericardial Mesothelioma

Pericardial Mesothelioma - Diagnosis, Treatment, and Prognosis in 2026

Pericardial mesothelioma is the rarest form of mesothelioma, accounting for less than 1 percent of all cases. It arises from the mesothelial lining of the pericardium — the fibrous sac that surrounds and protects the heart — and its proximity to the cardiac muscle makes it one of the most technically challenging cancers to treat.

The rarity of this disease means that most physicians will never encounter a case. Population-based registry data report a median overall survival of just 2.8 months. But that figure reflects the historical experience of patients treated at facilities with no specialized experience in this disease. At Memorial Sloan Kettering Cancer Center, median survival for patients who received multimodality therapy — the combination of surgery, chemotherapy, and radiation — was 70.3 months. The difference is not explained by biology alone. It is explained by who had access to specialized care and who did not.

Understanding pericardial mesothelioma — how it is diagnosed, what treatment options exist, and what the data show about outcomes — is essential for patients and families navigating this diagnosis.

Learn about all forms of mesothelioma.

Anatomy and Disease Behavior

The pericardium is a two-layered fibrous sac that envelops the heart and the proximal portions of the great vessels. The inner layer (visceral pericardium) adheres to the surface of the heart; the outer layer (parietal pericardium) forms the outer wall of the sac. The space between these layers contains a small amount of pericardial fluid that reduces friction during cardiac movement.

Pericardial mesothelioma can arise from either layer. As it grows, it encases the heart, compresses cardiac chambers, and invades the myocardium — the heart muscle itself. Myocardial invasion has been documented in approximately 64 percent of pericardial mesothelioma cases, which is one reason why surgical resection is more challenging than for pleural mesothelioma. The tumor literally grows into the organ that cannot be removed.

Symptoms and Presentation

The symptoms of pericardial mesothelioma reflect cardiac compression and pericardial inflammation:

• Chest pain — often the earliest symptom, frequently described as a dull or pressure-like discomfort

• Dyspnea — shortness of breath caused by cardiac compression or pericardial effusion restricting cardiac filling

• Cardiac arrhythmias — irregular heart rhythms resulting from myocardial involvement or pericardial inflammation

• Pericardial effusion — accumulation of fluid in the pericardial space, which can cause constrictive physiology

• Constitutional symptoms — fatigue, unintentional weight loss, fever

Because these symptoms mimic far more common cardiac conditions — pericarditis, heart failure, arrhythmia of other causes — pericardial mesothelioma is frequently misdiagnosed or significantly delayed in diagnosis. A patient with an unexplained pericardial effusion that does not respond to standard treatment, particularly one with a history of asbestos exposure, should be evaluated for pericardial mesothelioma.

Diagnosis

Pericardial mesothelioma requires tissue confirmation. This is both clinically necessary and technically demanding.

Pericardiocentesis (fluid cytology). Drainage of pericardial fluid provides specimen for cytological examination. However, fluid cytology alone is positive in only 11 to 23 percent of pericardial mesothelioma cases — a low sensitivity that means a negative fluid cytology does not exclude the diagnosis. Pericardiocentesis is used primarily for symptomatic relief of tamponade, not as the definitive diagnostic procedure.

Needle biopsy. Image-guided needle biopsy of the pericardium is generally preferred as the primary diagnostic approach when the disease is identifiable on imaging. It provides tissue for histological examination with less procedural risk than surgical approaches in patients who may have significant cardiac compromise.

Surgical biopsy. Video-assisted thoracoscopic surgery or open pericardial biopsy can provide larger tissue samples when needle biopsy is insufficient for diagnosis, but surgical risk must be carefully weighed in patients with cardiac involvement.

Immunohistochemistry. The 2021 WHO classification framework applies to pericardial mesothelioma, requiring demonstration of at least two positive mesothelial markers (such as calretinin and WT-1) combined with at least two negative markers that exclude metastatic carcinoma. Claudin-4 and CD15 are particularly useful as exclusion markers. BAP1 immunohistochemistry is critical — loss of BAP1 nuclear expression strongly supports a malignant diagnosis over reactive mesothelial proliferation. GATA3 has been reported with greater than 90 percent specificity for distinguishing pericardial mesothelioma from pericardial metastases of other cancers.

Staging

There is no formally validated TNM staging system for pericardial mesothelioma. The disease is typically characterized as localized or advanced based on the degree of pericardial involvement, myocardial invasion, and the presence of distant metastases. Because myocardial invasion is present in approximately 64 percent of cases, even "localized" disease often has features that complicate surgical planning.

Treatment

Pericardial mesothelioma requires multidisciplinary team (MDT) evaluation, ideally within 48 hours of diagnosis given the potential for acute cardiac decompensation. The rarity of this disease means that MDT discussions should involve cardiothoracic surgeons, oncologists, radiation oncologists, and cardiologists with mesothelioma experience — a combination that exists at only a handful of centers in the United States.

Surgery. Pericardiectomy — surgical removal of the pericardium — is the most ambitious surgical approach and is appropriate for patients with localized disease, adequate cardiac function, and adequate performance status. The procedure carries costs in the range of $45,000 to $60,000 and requires a surgeon with specific experience in this technically demanding operation.

In a series of patients who underwent tumor mass resection (rather than complete pericardiectomy), median survival was approximately 27 months — substantially better than the overall population median of 2.8 months. This suggests that surgical cytoreduction, even when complete resection is not possible, may extend survival in appropriately selected patients.

Pericardiocentesis — drainage of pericardial fluid — is a palliative procedure that relieves symptoms of tamponade but does not control tumor growth. It is appropriate for patients with symptomatic effusion who are not surgical candidates.

Chemotherapy. Platinum-based chemotherapy combined with pemetrexed is the standard systemic approach, extrapolated from the pleural mesothelioma evidence base. Median survival with chemotherapy for pericardial mesothelioma ranges from approximately 13 to 18 months in reported series. Some patients have been treated with bevacizumab added to the platinum-pemetrexed backbone.

Radiation. Intensity-modulated radiation therapy (IMRT) has been used in pericardial mesothelioma. In a series of 5 patients at Memorial Sloan Kettering, IMRT was safe to deliver and was part of the multimodality treatment protocol that achieved the most favorable survival outcomes in the literature.

Multimodality therapy (trimodality). The most striking survival data come from the MSK experience with multimodality treatment — pericardiectomy combined with systemic chemotherapy and radiation. In a 2022 report by Offin et al., patients who received trimodality therapy at MSK achieved a median overall survival of 70.3 months. The hazard ratio comparing trimodality patients to those who received more limited treatment was 0.14 — meaning that trimodality-treated patients had an 86 percent lower risk of death. This is one of the most favorable survival results reported for any pericardial mesothelioma series.

Immunotherapy. CheckMate 743 trial data, which demonstrated the efficacy of nivolumab plus ipilimumab in pleural mesothelioma (including in the non-epithelioid subgroup), are extrapolated to pericardial mesothelioma given the shared biology. Case reports and small series suggest response to checkpoint inhibitor therapy in pericardial mesothelioma. A 2025 expert consensus report (Ji et al.) describes immunotherapy outcomes reaching up to 24 months in reported pericardial cases. The appropriate first-line approach for most patients is combination immunotherapy with nivolumab plus ipilimumab.

Targeted therapies. Clinical trials specifically designed for mesothelioma with molecular targets are ongoing. The MiST1 trial (Fennell et al., 2021) evaluated rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma. The MiST2 trial (Fennell et al., 2022) evaluated abemaciclib in patients with p16ink4A-deficient mesothelioma. Both trials enrolled pericardial mesothelioma patients and represent mechanisms through which targeted therapy may be applied, particularly in patients with identified molecular vulnerabilities.

Prognosis

The prognosis for pericardial mesothelioma varies dramatically based on where and how treatment is received:

These ranges demonstrate that the disease is not uniformly fatal on the timeline suggested by population data. Patients with access to specialized centers and appropriate performance status for multimodality treatment have achieved survival measured in years.

Prognostic factors within pericardial mesothelioma:

• Histological subtype: Epithelioid mesothelioma carries median survival of 9 to 13 months overall; sarcomatoid 4 to 6 months; biphasic 6 to 10 months

• Sex: In some series, women have experienced meaningfully longer survival (median 6.7 months) than men (median 1.2 months), though small numbers limit interpretation

• Age: Patients aged 75 or older carry a hazard ratio of approximately 4.59 compared to younger patients, reflecting the combined effect of age-related comorbidities and limited tolerance for aggressive treatment

• Treatment intensity: Multimodality therapy at a specialized center is the strongest predictor of favorable outcomes

Living With Pericardial Mesothelioma

The cardiac location of this disease creates daily challenges beyond those of other mesothelioma subtypes. Physical activity, fluid balance, medication interactions with antiarrhythmics, and the psychological weight of a disease that directly involves the heart require specialized clinical management.

Physical activity and cardiac function. Disease or treatment-related effects on cardiac function may limit tolerance for physical activity. Cardiology follow-up is an essential component of the care team, not an adjunct to oncology care.

Nutrition. Fluid restrictions, appetite changes from chemotherapy side effects, and the increased caloric demands of active cancer treatment require individualized dietary planning. A registered dietitian with oncology experience can develop a plan that accounts for these competing needs.

Emotional and psychological wellbeing. Formal counseling or psychotherapy from an oncology-experienced clinician provides structured support for processing the emotional dimensions of this diagnosis. Peer support through patient communities — the Mesothelioma Applied Research Foundation maintains patient support networks — connects patients with others who have navigated similar experiences.

Advance care planning. Conversations about medical decision-making preferences — including preferences about resuscitation, mechanical ventilation, and the extent of aggressive intervention at end of life — are most productive while a patient is cognitively intact and physically stable. These conversations should not be deferred.

Best Centers for Treatment

Given the extreme rarity of pericardial mesothelioma and the technical demands of its management, the choice of treatment center is among the most consequential decisions a patient will make. Centers with documented experience include:

• Memorial Sloan Kettering Cancer Center (New York) — the institution with the largest published pericardial mesothelioma series and the trimodality protocol with the most favorable reported outcomes

• MD Anderson Cancer Center (Houston)

• Brigham and Women's Hospital (Boston)

• Penn Medicine (Philadelphia)

• University of Chicago Medicine (Chicago)

Asbestos and the Cause of Pericardial Mesothelioma

Pericardial mesothelioma is caused by asbestos exposure. The precise mechanism by which asbestos fibers reach the pericardium — whether via direct inhalation, lymphatic transport, or bloodstream migration — continues to be investigated. What is established is the epidemiological association: case-control studies have confirmed a strong link between occupational asbestos exposure and pericardial mesothelioma, and the latency period of 20 to 50 years from first exposure to diagnosis is consistent with the pattern for all asbestos-related malignancies.

Occupational industries implicated include the same shipbuilding, construction, petrochemical, power generation, and manufacturing trades that account for most pleural and peritoneal mesothelioma cases. Trade publications from the 1940s and 1950s — including articles in the asbestos industry's own trade magazine — document direct application of asbestos-containing products to pericardial surfaces in cardiac surgery, providing direct evidence that asbestos reached pericardial tissue through multiple routes.

Learn more about asbestos exposure by occupation. | Learn more about asbestos exposure in specific industries.

Legal Rights and Compensation

Asbestos Trust Fund Claims. More than 60 asbestos compensation trusts, holding combined assets in excess of $30 billion, were established when major asbestos manufacturers filed for bankruptcy. Trust fund claims are paper-based and do not require a lawsuit or courtroom appearance. Many mesothelioma patients receive initial distributions within months of filing. Most patients qualify for claims against multiple trusts. Our firm maintains a database of over 200,000 verified exposure sites that allows us to identify relevant trusts rapidly.

Asbestos Litigation Against Solvent Defendants. Not all asbestos manufacturers went bankrupt. Companies that remain solvent and whose products caused your exposure can be sued directly. Lawsuits can recover economic damages including medical expenses and lost income, and non-economic damages including pain and suffering.

VA Disability Benefits. Military veterans diagnosed with pericardial mesothelioma are entitled to specific benefits through the Department of Veterans Affairs. Mesothelioma is on the VA's list of diseases with presumptive service connection for veterans who served in certain roles and time periods, and disability ratings are typically 100%. VA benefits and civil legal compensation can be pursued simultaneously.

Social Security Disability and Compassionate Allowances. Mesothelioma qualifies for the SSA's Compassionate Allowances program, which fast-tracks disability determinations to weeks rather than months.

Explore all your legal options. | Learn about VA benefits for mesothelioma.

How Our Firm Can Help

The Law Offices of Justinian C. Lane, Esq. – PLLC represents mesothelioma patients and families on a contingency fee basis — no upfront cost, no retainer, and no legal fee unless we recover compensation for you.

The consultation is free. The process is confidential. There is no obligation. Call 833-4-ASBESTOS (833-427-2378) for a free, confidential consultation, or schedule your consultation online.

References

1. Ji Q, Xu C, Wang Q, et al. Expert consensus on the diagnosis and treatment of malignant pericardial mesothelioma. Med Research. 2025;1:122-130.

2. Stacchiotti S, Frezza AM, Blay JY, et al. Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934-2942.

3. Stella S, Consonni D, Ceresoli GL, et al. Pericardial mesothelioma: Diagnostic and therapeutic management, a population-based study in Italy. Cancers. 2025;17(23):3865.

4. Thomason R, Schlegel W, Lucca M, Cummings S, Lee S. Primary malignant mesothelioma of the pericardium: Case report and literature review. Texas Heart Institute Journal. 1994;21(2):170-174.

5. Guo J, Ronco C, Kellum JA. The pericardium in health and disease. Critical Reviews in Oncology/Hematology. 2005;55(3):231-240.

6. McGehee E, Gerber DE, Reisch J, Dowell JE. Treatment and outcomes of primary pericardial mesothelioma: A contemporary review of 103 published cases. Clinical Lung Cancer. 2019;20(3):e152-e157.

7. Didier AJ, Li M, Gheeya J, et al. Trends in mesothelioma mortality in the United States between 1999 and 2020. JTO Clinical and Research Reports. 2025;6:100804.

8. Offin M, De Silva D, Sauter JL, et al. Multimodality therapy in patients with primary pericardial mesothelioma. Journal of Thoracic Oncology. 2022;17(12):1428-1432.

9. "The Heart — And Asbestos." Asbestos (trade magazine). July 1943:18.

10. "Asbestos for Heart Trouble." Asbestos (trade magazine). March 1950:11.

11. Churg A, Warnock ML, Bensch KG. Malignant mesothelioma arising after direct application of asbestos and fiber glass to the pericardium. American Review of Respiratory Disease. 1978;118(2):419-424.

12. Kahn EI, Rohl AN, Barrett EW, Suzuki Y. Primary pericardial mesothelioma following exposure to asbestos. Environmental Research. 1980;23(2):270-281.

13. Beck B, Konetzke G, Ludwig V, Röthig W, Sturm W. Malignant pericardial mesotheliomas and asbestos exposure: A case report. American Journal of Industrial Medicine. 1982;3(2):149-159.

14. Marinaccio A, Consonni D, Mensi C, et al. Association between asbestos exposure and pericardial and tunica vaginalis testis malignant mesothelioma. Scandinavian Journal of Work, Environment & Health. 2020;46(6):609-617.

15. Mezei G, Chang ET, Mowat FS, Moolgavkar SH. Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis. Annals of Epidemiology. 2017;27(5):348-359.

16. Arrossi AV. Pericardial mesotheliomas. Advances in Anatomic Pathology. 2023;30(4):253-258.

17. Ravindra K, Vanchiere C, Ferrari VA. A rare cause of constrictive pericarditis: Primary pericardial mesothelioma. JACC Case Reports. 2025;30:103802.

18. Brydges H, Yin K, Balasubramaniyan R, et al. Primary pericardial mesothelioma: A population-based propensity score-matched analysis. Seminars in Thoracic and Cardiovascular Surgery. 2022;34(4):1113-1119.

19. Wang D, Wang YH, Chu SC. Case report: Early diagnosis and bevacizumab-based chemotherapy for primary pericardial mesothelioma. Frontiers in Cardiovascular Medicine. 2023;10:1257373.

20. Borrelli E, Babcock Z, Kogut S. Costs of medical care for mesothelioma. Rare Tumors. 2019;11:2036361319863498.

21. Fujita K, Kato T, Yoshida M, Yano H, Kobayashi M. Three-year survival after surgery for primary malignant pericardial mesothelioma: Report of a case. Surgery Today. 2013;43(12):1366-1370.

22. Arponen O, Järvinen T, Ilonen I, et al. Primary pericardial mesothelioma: A case report of a patient treated with an immune checkpoint inhibitor as the second-line treatment. Acta Oncologica. 2021;60(5):687-691.

23. Scherpereel A, Antonia S, Bautista Y, et al. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: Patient-reported outcomes in CheckMate 743. Lung Cancer. 2022;167:8-16.

24. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 2022;33(5):488-499.

25. Fennell DA, King A, Mohammed S, et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1). Lancet Respiratory Medicine. 2021;9(6):593-600.

26. Fennell DA, King A, Mohammed S, et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2). Lancet Oncology. 2022;23(3):374-381.

27. Marinaccio A, Binazzi A, Di Marzio D, et al. Incidence of extrapleural malignant mesothelioma and asbestos exposure, from the Italian national register. Occupational and Environmental Medicine. 2010;67(11):760-765.

28. Sauter JL, Dacic S, Galateau-Salle F, et al. The 2021 WHO classification of tumors of the pleura: Advances since the 2015 classification. Journal of Thoracic Oncology. 2022;17(5):608-622.

29. Panou V, Gadiraju M, Wolin A, et al. Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma. Journal of Clinical Oncology. 2018;36(28):2863-2871.

30. Cao S, Jin S, Cao J, et al. Malignant pericardial mesothelioma: A systematic review of current practice. Herz. 2018;43(1):61-68.